Skip to main content
SpringerLink
Log in

Biostatistics in Clinical Oncology

  • Chapter
  • First Online:
'Essentials of Cancer Genomic, Computational Approaches and Precision Medicine

  • 749 Accesses

Abstract

There is a real need for the application of statistics in oncology research. Statistics is required to support oncology research through study design, analysis, and meta-analysis. This chapter is about the illustration of different statistics section important in oncology research.

The application of statistical methods, in the design and interpretation of oncology research, helps different substantial outcomes as compared to the classical approach.

Statistical methods can easily handle different complex issue. The issue may be due to data and study design in oncology. It is hoped that this statistical review will be a useful resource to the oncologist. It will promote quality experimental research in oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Yuan Y, Hunt RH (2009) Systematic reviews: the good, the bad, and the ugly. Am J Gastroenterol 104(5):1086–1092

    Article  PubMed  Google Scholar 

  2. Gotzsche PC (2000) Why we need a broad perspective on meta-analysis. It may be crucially important for patients. BMJ 321(7261):585–586

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188

    Article  CAS  PubMed  Google Scholar 

  4. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    CAS  PubMed  Google Scholar 

  5. Cochran WG (1994) The combination of estimates from different experiments. Biometrics 10:101–129

    Article  Google Scholar 

  6. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  PubMed Central  Google Scholar 

  7. Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889–894

    Article  CAS  PubMed  Google Scholar 

  8. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Higgins JPT, Green S (eds) (2009) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration, 2009. www.cochrane-handbook.org

  10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34

    Article  PubMed  Google Scholar 

  11. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012

    Article  PubMed  Google Scholar 

  12. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896–1900

    Article  CAS  PubMed  Google Scholar 

  13. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC (1992) A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: treatments for myocardial infarction. JAMA 268:240–248

    Article  CAS  PubMed  Google Scholar 

  14. Oxman AD, Guyatt GH (1993) The science of reviewing research. Ann N Y Acad Sci 703:125–133

    Article  CAS  PubMed  Google Scholar 

  15. Greenland S (1994) Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 140:290–296

    Article  CAS  PubMed  Google Scholar 

  16. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J (2001) Comparison of evidence of treatment effects in randomized and non-randomized studies. JAMA 286:821–830

    Article  CAS  PubMed  Google Scholar 

  17. Haidich AB (2010) Meta-analysis in medical research. Hippokratia 14(1):29–37

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Chalmers I (1993) The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann N Y Acad Sci 703:156–163

    Article  CAS  PubMed  Google Scholar 

  19. Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340:c221

    Article  PubMed  Google Scholar 

  20. Tierney JF, Vale C, Riley R, Smith CT, Stewart L, Clarke M, Rovers M (2015) Individual participant data (IPD) meta-analyses of randomised controlled trials: guidance on their use. PLoS Med 12(7):e1001855

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kalter J, Sweegers MG, Verdonck-de Leeuw IM, Brug J, Buffart LM (2019) Development and use of a flexible data harmonization platform to facilitate the harmonization of individual patient data for meta-analyses. BMC Res Notes 12(1):164

    Article  PubMed  PubMed Central  Google Scholar 

  22. Buffart LM, Kalter J, Chinapaw MJ, Heymans MW, Aaronson NK, Courneya KS, Jacobsen PB, Newton RU, Verdonck-de Leeuw IM, Brug J (2013) Predicting Optimal Cancer Rehabilitation and Supportive Care (POLARIS): rationale and design for meta-analyses of individual patient data of randomized controlled trials that evaluate the effect of physical activity and psychosocial interventions on health-related quality of life in cancer survivors. Syst Rev 2(1):75

    Article  PubMed  PubMed Central  Google Scholar 

  23. Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Lucia A, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Arbane G, Schmidt ME, Potthoff K, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Garrod R, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J (2017) Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev 52:91–104

    Article  PubMed  Google Scholar 

  24. Kalter J, Verdonck-de Leeuw IM, Sweegers MG, Aaronson NK, Jacobsen PB, Newton RU, Courneya KS, Aitken JF, Armes J, Arving C, Boersma LJ, Braamse AMJ, Brandberg Y, Chambers SK, Dekker J, Ell K, Ferguson RJ, Gielissen MFM, Glimelius B, Goedendorp MM, Graves KD, Heiney SP, Horne R, Hunter MS, Johansson B, Kimman ML, Knoop H, Meneses K, Northouse LL, Oldenburg HS, Prins JB, Savard J, van Beurden M, van den Berg SW, Brug J, Buffart LM (2018) Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: an individual patient data meta-analysis of 22 RCTs. Psychooncology 27(4):1150–1161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gonzalez FJ (1995) Genetic polymorphism and cancer susceptibility: 14th Sapporo Cancer seminar. Cancer Res 55:710–715

    CAS  PubMed  Google Scholar 

  26. Pabalan N, Bapat B, Sung L, Jarjanazi H, Francisco-Pabalan O, Ozcelik H (2008) Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomark Prev 17:2773–2781

    Article  CAS  Google Scholar 

  27. Pabalan N, Francisco-Pabalan O, Sung L, Jarjanazi H, Ozcelik H (2010) Meta-analysis of two polymorphisms, Lys751Gln and Asp312Asn, in the DNA repair gene, XPD (ERCC2) with breast cancer. Breast Cancer Res Treat 17:27

    Google Scholar 

  28. Brennan P (2012) Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 23(3):381–387

    Article  Google Scholar 

  29. Zintzaras E, Lau J (2008) Trends in meta-analysis of genetic association studies. J Hum Genet 53:1–9

    Article  CAS  PubMed  Google Scholar 

  30. Taioli E (2005) Biomarkers of genetic susceptibility to cancer: applications to epidemiological studies. Future Oncol 1:51–56

    Article  CAS  PubMed  Google Scholar 

  31. Ioannidis JP (2004) The value of meta-analysis in rheumatology research. Autoimmun Rev 3(Suppl 1):S57–S59

    PubMed  Google Scholar 

  32. Pabalan N (2010) Meta-analysis in cancer genetics. Asian Pacific J Cancer Prev 11:33–38

    Google Scholar 

  33. Morris RD (1994) Meta-analysis in cancer epidemiology. Environ Health Perspect 102(Suppl 8):61–66

    Article  PubMed  PubMed Central  Google Scholar 

  34. Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118(8):622–629

    Article  CAS  PubMed  Google Scholar 

  35. Spilker B (ed) (1996) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia, pp 1–1259

    Google Scholar 

  36. Testa MA, Simonson DC (1996) Assessment of quality-of-life outcomes. N Engl J Med 334(13):835–840

    Article  CAS  PubMed  Google Scholar 

  37. Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273(1):59–65

    Article  CAS  PubMed  Google Scholar 

  38. Oldridge N, Gottlieb M, Guyatt G, Jones N, Streiner D, Feeny D (1998) Predictors of health-related quality of life with cardiac rehabilitation after acute myocardial infarction. J Cardpulm Rehabil 18(2):95–103

    Article  CAS  Google Scholar 

  39. Boscolo-Rizzo P, Maronato F, Marchiori C, Gava A, Da Mosto MC (2008) Long-term quality of life after total laryngectomy and postoperative radiotherapy versus concurrent chemoradiotherapy for laryngeal preservation. Laryngoscope 118(2):300–306

    Article  PubMed  Google Scholar 

  40. Hörnquist JO (1990) Quality of life: concept and assessment. Scand J Soc Med 18(1):69–79

    Article  PubMed  Google Scholar 

  41. Thatcher N, Hopwood P, Anderson H (1997) Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur J Cancer 33(Suppl 1):S8–S13

    Article  CAS  PubMed  Google Scholar 

  42. Mauer ME, Bottomley A, Taphoorn MJ (2008) Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in experimental trials and clinical practice. Curr Opin Neurol 21(6):745–753

    Article  PubMed  Google Scholar 

  43. Hiatt RA, Breen N (2008) The social determinants of cancer: a challenge for trans disciplinary science. Am J Prev Med 35:S141–S150

    Article  PubMed  Google Scholar 

  44. Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP, Partridge AH (2012) Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer 12(2):119–126

    Article  PubMed  Google Scholar 

  45. Zebrack BJ, Landier W (2011) The perceived impact of cancer on quality of life for post-treatment survivors of childhood cancer. Qual Life Res 20(10):1595–1608

    Article  PubMed  Google Scholar 

  46. Osoba D (2011) Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol 3:57–71

    Article  PubMed  PubMed Central  Google Scholar 

  47. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671–679

    Article  Google Scholar 

  48. Efficace F, Fayers P, Pusic A, Cemal Y, Yanagawa J, Jacobs M, la Sala A, Cafaro V, Whale K, Rees J, Blazeby J (2015) European Organization for Research and Treatment of Cancer quality-of-life group (patient-reported outcome measurements over time in oncology registry). Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: a pooled analysis of 557 trials. Cancer 121:3335–3342

    Article  PubMed  Google Scholar 

  49. Stockler MR, Hilpert F, Friedlander M et al (2014) Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 32:1309–1316

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E (2014) Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 32(13):1309–1316

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Parab S, Bhalerao S (2010) Choosing statistical test. Int J Ayurveda Res 1(3):187–191

    Article  PubMed  PubMed Central  Google Scholar 

  52. Roy J, Winter C, Schroeder M (2016) Meta-analysis of Cancer gene profiling data. Methods Mol Biol 1381:211–222

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Genetics Laboratory, Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, India

    Gaurav Roy

  2. Section of Biostatistics, Centre for Cancer Epidemiology, Tata Memorial Centre & Homi Bhaba National Institute, Mumbai, India

    Atanu Bhattacharjee

  3. Microbiology and Biotechnology Research Lab, Fatima Jinnah Women University, Old Presidency, Pakistan

    Iqra Khan

Authors
  1. Gaurav Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atanu Bhattacharjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iqra Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fatima Jinnah Women University, Rawalpindi, Pakistan

    Nosheen Masood

  2. Fatima Jinnah Women University, Rawalpindi, Pakistan

    Saima Shakil Malik

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Roy, G., Bhattacharjee, A., Khan, I. (2020). Biostatistics in Clinical Oncology. In: Masood, N., Shakil Malik, S. (eds) 'Essentials of Cancer Genomic, Computational Approaches and Precision Medicine. Springer, Singapore. https://doi.org/10.1007/978-981-15-1067-0_14

Download citation

Publish with us

Policies and ethics

Search

Navigation